// App-Quantinova.ai

: Akt2 Mediates Glucocorticoid Resistance in Acute Lymphoblastic Leukemia through FoxO3a/Bim Axis and Serves As a Direct Target for Resistance Reversal

Researchers

Presenter

  • Mixue Xie

Principal Investigators

  • Yanhui Xie

  • Apeng Yang

  • Jiexian Ma

  • Min Wu

  • Youxin Jin

Medical Centers

  • Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

  • Shanghai Huadong Hospital Affiliated To Fudan University, Shanghai, CHN

  • The First Department of Chemotherapy,The First Affiliated Hospital, Fujian Medical University,Fuzhou, Fuzhou, China

  • Cancer Hospital Affiliated to Fudan University, Shanghai, China

  • Shanghai Jiaotong University, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Acute lymphoblastic leukemia

  • Glucocorticoid resistance

  • Solid malignancies

  • Hematology-oncology disease

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

Drug/Treatment

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved